跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
AMIKACIN SULFATE INJECTION - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
AMIKACIN SULFATE INJECTION
Authorized
STANDARD
AMIKACIN SULFATE INJECTION
Jamp Pharma Corporation
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
5469d7ec14c32276
Company
Jamp Pharma Corporation
Type
Standard
Approval Details
Approval Id
5469d7ec14c32276
Drug Approval Canada Name
AMIKACIN SULFATE INJECTION
Product Name
AMIKACIN SULFATE INJECTION
Status
Marketed
Status Date
2023-10-06
Original Market Date
2023-10-06
Din
02529459
Drug Class
Human
Dosage Form
Solution
Route Of Administration
Intramuscular , Intravenous
Schedule
Prescription
Ahfs
08:12.02
Atc Original
J01GB06 AMIKACIN
Atc Name
j 01 gb 06
Aig Number
0111922001
Company Name
Jamp Pharma Corporation
Company Address
1310 Rue Nobel, Boucherville, Quebec, Canada, J4B 5H3
Company Detail Path
/organization/jamp-pharma-corporation
Company Information
Pharmaceutical Company Name
Jamp Pharma Corporation
Country Name
Canada
Province Name
British Columbia
City Name
chilliwack,british columbia,country_ca
Address
8065 Aitken Rd
Active Ingredients
AMIKACIN (AMIKACIN SULFATE)
250 MG / ML
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
5469d7ec14c32276
Type
Standard
Back to Health Canada Approvals